GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » E10

Windtree Therapeutics (Windtree Therapeutics) E10 : $-159,339.00 (As of Dec. 2023)


View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Windtree Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-13.320. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-159,339.00 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 23.60% per year. During the past 5 years, the average E10 Growth Rate was 26.20% per year. During the past 10 years, the average E10 Growth Rate was 31.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Windtree Therapeutics was 50.90% per year. The lowest was 8.40% per year. And the median was 28.60% per year.

As of today (2024-05-05), Windtree Therapeutics's current stock price is $4.94. Windtree Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-159,339.00. Windtree Therapeutics's Shiller PE Ratio of today is .


Windtree Therapeutics E10 Historical Data

The historical data trend for Windtree Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windtree Therapeutics E10 Chart

Windtree Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -496,364.00 -357,885.00 -301,850.00 -237,031.00 -159,339.00

Windtree Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -237,031.00 -212,320.00 -194,443.00 -173,835.00 -159,339.00

Competitive Comparison of Windtree Therapeutics's E10

For the Biotechnology subindustry, Windtree Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windtree Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's Shiller PE Ratio falls into.



Windtree Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Windtree Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-13.32/129.4194*129.4194
=-13.320

Current CPI (Dec. 2023) = 129.4194.

Windtree Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -102,464.000 99.695 -133,014.654
201406 -94,848.200 100.560 -122,068.995
201409 -101,107.000 100.428 -130,294.672
201412 -110,027.000 99.070 -143,733.435
201503 -107,779.000 99.621 -140,017.461
201506 -100,230.000 100.684 -128,835.956
201509 -145,649.000 100.392 -187,762.970
201512 -72,582.800 99.792 -94,131.642
201603 -91,453.900 100.470 -117,804.934
201606 -69,437.900 101.688 -88,374.268
201609 -53,609.000 101.861 -68,112.866
201612 -41,006.200 101.863 -52,099.520
201703 -69,649.700 102.862 -87,632.020
201706 -37,353.800 103.349 -46,776.473
201709 -26,749.100 104.136 -33,243.698
201712 2,069.460 104.011 2,574.997
201803 -3,780.000 105.290 -4,646.288
201806 -2,187.000 106.317 -2,662.234
201809 -2,808.000 106.507 -3,412.083
201812 -1,954.880 105.998 -2,386.834
201903 -549.000 107.251 -662.479
201906 -540.000 108.070 -646.681
201909 -594.000 108.329 -709.642
201912 -567.001 108.420 -676.820
202003 -432.000 108.902 -513.392
202006 -567.000 108.767 -674.659
202009 -486.000 109.815 -572.762
202012 -387.000 109.897 -455.749
202103 -459.000 111.754 -531.554
202106 -1,278.000 114.631 -1,442.868
202109 -279.000 115.734 -311.991
202112 -380.520 117.630 -418.659
202203 -258.480 121.301 -275.779
202206 -534.240 125.017 -553.054
202209 -117.180 125.227 -121.103
202212 -234.180 125.222 -242.030
202303 -85.680 127.348 -87.074
202306 -29.520 128.729 -29.678
202309 -15.480 129.860 -15.428
202312 -13.320 129.419 -13.320

Add all the adjusted EPS together and divide 10 will get our e10.


Windtree Therapeutics  (NAS:WINT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Windtree Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Windtree Therapeutics (Windtree Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug-delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
Executives
Craig Fraser director, officer: Chief Executive Officer AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew officer: VP, Controller, & CAO WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck director 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill officer: SVP & CFO 4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc. 10 percent owner 7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc. 10 percent owner 7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman officer: SVP & General Counsel 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis officer: SVP & COO ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson officer: SVP, Chief Development Officer 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh director 75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott director
Joseph M Mahady director 16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber director 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976

Windtree Therapeutics (Windtree Therapeutics) Headlines

From GuruFocus